China Gastrointestinal Drugs Market Analysis

China Gastrointestinal Drugs Market Analysis


$ 3999

China Gastrointestinal Drugs Market is projected to grow from $xx Mn in 2022 to $xx Mn by 2030, registering a CAGR of xx% during the forecast period of 2022 - 2030. The rising prevalence of gastrointestinal problems, caused by factors such as changing lifestyles, dietary habits, and an ageing population, is one of the main drivers for gastrointestinal medications. Technological advances in drug research and targeted medicines, which provide more effective treatment alternatives, also contribute to market growth. Furthermore, as people become more aware of and diagnose gastrointestinal diseases, the need for medications to treat these conditions grows. Pfizer Inc., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Bristol Myers Squibb Company, Eli Lilly and Company, Merck & Co., Inc., and Allergan plc are among the major global competitors in the gastrointestinal drugs market.

ID: IN10CNPH283 CATEGORY: Pharmaceuticals GEOGRAPHY: China AUTHOR: Dr. Medha Sansanwal

Buy Now

China Gastrointestinal Drugs Market Analysis Summary

China Gastrointestinal Drugs Market is valued at around $4254.1 Mn in 2022 and is projected to reach $7200.8 Mn by 2030, exhibiting a CAGR of 6.8% during the forecast period 2023-2030.

In the general population, the point prevalence of having a digestive ailment was 24%. The increasing prevalence of gastrointestinal problems, caused by factors such as changing lifestyles, dietary habits, and an aging population, is one of the main drivers for gastrointestinal medications. Technological improvements in drug research and targeted therapies also help market expansion by giving more effective treatment alternatives. Furthermore, the increased knowledge and diagnosis of gastrointestinal problems fuels the market for medications to treat these ailments. Pfizer Inc., Johnson & Johnson, AbbVie Inc., Takeda Pharmaceutical Company Limited, AstraZeneca PLC, GlaxoSmithKline plc, Bristol Myers Squibb Company, Eli Lilly and Company, Merck & Co., Inc., and Allergan plc are among the major global competitors in the gastrointestinal drugs market.

Market Dynamics

Market Growth Drivers

  1. Increasing Prevalence of Gastrointestinal Disorders: The rising incidence and prevalence of gastrointestinal disorders, such as GERD, peptic ulcers, IBD, and IBS, are driving the demand for gastrointestinal drugs
  2. Growing Aging Population: The aging population is more prone to gastrointestinal disorders, contributing to the increased demand for medications to manage these conditions
  3. Changing Lifestyle and Dietary Habits: Unhealthy lifestyle choices, including poor diet, sedentary lifestyle, and high-stress levels, are leading to a higher occurrence of gastrointestinal disorders, creating a need for effective drugs
  4. Technological Advancements: Advancements in pharmaceutical research and development have led to the introduction of innovative and targeted therapies for gastrointestinal disorders, driving market growth

Market Restraints

  1. Side Effects and Safety Concerns: Gastrointestinal drugs may be associated with potential side effects and safety concerns. Adverse reactions and long-term effects can limit their use and affect patient compliance
  2. Generic Competition: Loss of patent exclusivity for certain branded gastrointestinal drugs leads to increased competition from generic versions, impacting market growth for original manufacturers
  3. Stringent Regulatory Environment: Strict regulations and requirements for drug approval can prolong the time and cost associated with bringing new gastrointestinal drugs to market, impeding market growth
  4. Preference for Non-pharmacological Approaches: Some patients and healthcare providers prefer non-pharmacological approaches, such as lifestyle modifications and dietary changes, which may reduce the reliance on medications and limit market growth

Competitive Landscape

Key Players

  • Pfizer Inc.
  • Johnson & Johnson
  • AbbVie Inc.
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca PLC
  • GlaxoSmithKline plc
  • Bristol Myers Squibb Company
  • Eli Lilly and Company
  • Merck & Co., Inc.
  • Allergan plc.

1. Executive Summary
1.1 Disease Overview
1.2 Global Scenario
1.3 Country Overview
1.4 Healthcare Scenario in Country
1.5 Patient Journey
1.6 Health Insurance Coverage in Country
1.7 Active Pharmaceutical Ingredient (API)
1.8 Recent Developments in the Country

2. Market Size and Forecasting
2.1 Epidemiology of Disease
2.2 Market Size (With Excel & Methodology)
2.3 Market Segmentation (Check all Segments in Segmentation Section)

3. Market Dynamics
3.1 Market Drivers
3.2 Market Restraints

4. Competitive Landscape
4.1 Major Market Share

4.2 Key Company Profile (Check all Companies in the Summary Section)

4.2.1 Company
4.2.1.1 Overview
4.2.1.2 Product Applications and Services
4.2.1.3 Recent Developments
4.2.1.4 Partnerships Ecosystem
4.2.1.5 Financials (Based on Availability)

5. Reimbursement Scenario
5.1 Reimbursement Regulation
5.2 Reimbursement Process for Diagnosis
5.3 Reimbursement Process for Treatment

6. Methodology and Scope

sexy Gastrointestinal Drugs Market Segmentation

By Drug Class

  • Proton Pump Inhibitors (PPIs)
  • H2 Receptor Antagonists (H2RAs)
  • Antacids
  • Antiemetics
  • Prokinetics
  • Antidiarrheals
  • Laxatives
  • Antispasmodics
  • Others

By Route of Administration

  • Oral
  • Parenteral
  • Rectal

By Indication

  • Gastroesophageal Reflux Disease (GERD)
  • Peptic Ulcers
  • Inflammatory Bowel Disease (IBD)
  • Gastroenteritis
  • Irritable Bowel Syndrome (IBS)
  • Others

By Distribution Channel

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Methodology for Database Creation

Our database offers a comprehensive list of healthcare centers, meticulously curated to provide detailed information on a wide range of specialties and services. It includes top-tier hospitals, clinics, and diagnostic facilities across 30 countries and 24 specialties, ensuring users can find the healthcare services they need.​

Additionally, we provide a comprehensive list of Key Opinion Leaders (KOLs) based on your requirements. Our curated list captures various crucial aspects of the KOLs, offering more than just general information. Whether you're looking to boost brand awareness, drive engagement, or launch a new product, our extensive list of KOLs ensures you have the right experts by your side. Covering 30 countries and 36 specialties, our database guarantees access to the best KOLs in the healthcare industry, supporting strategic decisions and enhancing your initiatives.

How Do We Get It?

Our database is created and maintained through a combination of secondary and primary research methodologies.

1. Secondary Research

With many years of experience in the healthcare field, we have our own rich proprietary data from various past projects. This historical data serves as the foundation for our database. Our continuous process of gathering data involves:

  • Analyzing historical proprietary data collected from multiple projects.
  • Regularly updating our existing data sets with new findings and trends.
  • Ensuring data consistency and accuracy through rigorous validation processes.

With extensive experience in the field, we have developed a proprietary GenAI-based technology that is uniquely tailored to our organization. This advanced technology enables us to scan a wide array of relevant information sources across the internet. Our data-gathering process includes:

  • Searching through academic conferences, published research, citations, and social media platforms
  • Collecting and compiling diverse data to build a comprehensive and detailed database
  • Continuously updating our database with new information to ensure its relevance and accuracy

2. Primary Research

To complement and validate our secondary data, we engage in primary research through local tie-ups and partnerships. This process involves:

  • Collaborating with local healthcare providers, hospitals, and clinics to gather real-time data.
  • Conducting surveys, interviews, and field studies to collect fresh data directly from the source.
  • Continuously refreshing our database to ensure that the information remains current and reliable.
  • Validating secondary data through cross-referencing with primary data to ensure accuracy and relevance.

Combining Secondary and Primary Research

By integrating both secondary and primary research methodologies, we ensure that our database is comprehensive, accurate, and up-to-date. The combined process involves:

  • Merging historical data from secondary research with real-time data from primary research.
  • Conducting thorough data validation and cleansing to remove inconsistencies and errors.
  • Organizing data into a structured format that is easily accessible and usable for various applications.
  • Continuously monitoring and updating the database to reflect the latest developments and trends in the healthcare field.

Through this meticulous process, we create a final database tailored to each region and domain within the healthcare industry. This approach ensures that our clients receive reliable and relevant data, empowering them to make informed decisions and drive innovation in their respective fields.

To request a free sample copy of this report, please complete the form below.


We value your inquiry and offer free customization with every report to fulfil your exact research needs.


Last updated on: 27 February 2024
Updated by: Ritu Baliya

Related reports (by category)


Related reports (by geography)


subscribe to our newsletter
up